GeneralBullishBlockonomi · Jun 86/10
📰
Tango Therapeutics (TNGX) Stock Soars 45% Following Breakthrough Pancreatic Cancer Data
Tango Therapeutics (TNGX) stock surged 45% following the announcement of clinical trial data showing a 92% response rate in pancreatic cancer patients. The company plans to advance to Phase 3 trials in 2026, marking significant progress in oncology treatment development.